Lyophilisation, Reconstitution and Stability: Variables That Affect Peptide Research Material

Why peptides are supplied lyophilised

Lyophilisation, or freeze-drying, removes water from a frozen peptide solution by sublimation under vacuum, leaving a dry solid cake. It is the standard format for supplying research peptides because peptides in aqueous solution are, in general, considerably less stable than the same peptide in dry, frozen form. Water enables the principal chemical degradation pathways that affect peptides — hydrolysis of the peptide backbone, deamidation of asparagine and glutamine side chains, and oxidation of susceptible residues such as methionine, tryptophan and cysteine — each of which proceeds far more slowly in the absence of bulk water.

The lyophilisation process itself is not without risk to the material: freezing can concentrate solutes and shift pH in ways that stress a peptide, and the choice of excipients (bulking agents, cryoprotectants such as mannitol or trehalose, and pH-buffering salts) affects both the physical appearance of the resulting cake and the degradation rate on storage. A well-formulated lyophilised peptide typically forms a coherent, easily dissolved cake; a poorly formulated one may collapse, appear glassy, or resist reconstitution — none of which is directly a purity signal, but each of which is informative about formulation quality.

Reconstitution: solvent choice and mechanical handling

Reconstitution refers to redissolving the lyophilised cake in an appropriate diluent immediately before use in an experiment. The choice of diluent depends on the peptide's solubility profile: many peptides dissolve adequately in sterile water or a simple aqueous buffer, while more hydrophobic sequences, or those prone to aggregation at neutral pH, may require a small volume of a co-solvent such as dilute acetic acid or, less commonly, a small percentage of an organic solvent, before dilution into the working buffer.

Mechanical handling during reconstitution also matters. Vigorous shaking or vortexing of a peptide solution can promote aggregation, particularly at an air-liquid interface where partially unfolded peptide chains can adsorb and denature; a gentle swirling motion, or resting the vial briefly to allow passive dissolution before gentle mixing, is generally preferred in laboratory protocols for sensitive sequences. Filtration through a low-protein-binding membrane (commonly polyethersulfone rather than cellulose acetate, which can adsorb peptides) is a standard step where sterility or particulate removal is required for the downstream assay.

Temperature at the point of reconstitution is a further variable: some peptides dissolve more readily at room temperature, while others show reduced aggregation when reconstitution and initial handling are performed on ice. Because this varies by sequence and formulation, laboratories should consult sequence-specific solubility data or supplier documentation rather than applying a single universal protocol.

What determines post-reconstitution stability

Once in solution, a peptide's stability window is governed by several interacting variables, each of which has been studied in the pharmaceutical peptide-formulation literature. Temperature is the most obvious: degradation reactions generally follow Arrhenius-type kinetics, so storage at 2–8°C substantially slows chemical degradation relative to room temperature, and storage at −20°C or below slows it further still, though repeated freeze-thaw cycling introduces its own aggregation risk through repeated ice-crystal formation at the solution's surface and interfaces.

pH is a second major variable, with an optimum that is sequence-dependent: peptides containing asparagine-glycine or asparagine-serine motifs are particularly prone to deamidation at neutral-to-alkaline pH, while peptides with acid-labile bonds may instead degrade preferentially under acidic conditions. Concentration also matters, both because dilute solutions can lose material to non-specific adsorption onto vial or tubing surfaces, and because concentrated solutions of aggregation-prone peptides are more likely to self-associate. Finally, light exposure can drive photo-oxidation of aromatic residues in some sequences, which is why amber vials or foil wrapping are recommended for light-sensitive peptides during storage.

• Storage temperature after reconstitution: refrigerated versus frozen versus room temperature.
• Solution pH relative to the sequence's known deamidation- and hydrolysis-sensitive motifs.
• Peptide concentration, affecting both surface adsorption losses and aggregation propensity.
• Number of freeze–thaw cycles the reconstituted aliquot has been through.
• Presence or absence of light exposure and the resulting photo-oxidation risk for aromatic residues.
• Vial and tubing surface chemistry, since low-protein-binding plasticware reduces non-specific adsorption losses.

Practical implications for experimental design

Because degradation is time-, temperature- and pH-dependent rather than a fixed cliff-edge event, the practical laboratory convention is to prepare single-use aliquots at the point of reconstitution, store them at the coldest temperature consistent with the sequence's known freezing tolerance, and use each aliquot once rather than repeatedly freeze-thawing a stock solution. Where an experiment depends on a specific receptor interaction — for example the GLP-1 receptor pharmacology summarised in our overview of [semaglutide](/research/semaglutide), or the tissue-repair-associated signalling discussed for [BPC-157](/research/bpc-157) — a degraded or aggregated sample can materially change the observed result independent of the peptide's underlying pharmacology, so documenting reconstitution date, diluent, storage condition and time-in-solution alongside experimental data is good laboratory practice.

Laboratories should also be cautious about extrapolating a stability figure quoted for one peptide, buffer and concentration to a different peptide or condition. Published forced-degradation and real-time stability studies are sequence- and formulation-specific, and a stability claim without a stated buffer, concentration, temperature and time point is not directly actionable.